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Testosterone and its powerful metabolite dihydrotestosterone can be used in 
a variety of disorders to improve the symptoms or restore androgen plasma 
levels. To increase their duration and effects, androgens are administered in 
different pharmaceutical forms, in particular as esters of carboxylic acids. 
The goal of our research was to use specific unsaturated fatty acids esterified 
with androgens to improve the pharmaceutical characteristics of the esters as 
well as their biological effects and safety. Oleic acid, linoleic acid and the n-3 
fatty acids, alpha-linolenic acid, eicosapentaenoic acid and docosahexaenoic 
acid, were esterified with androgens. Their cytotoxicity was evaluated in 
mouse NIH3T3 and human astrocyte cell lines. The esters showed good 
tolerability and no in vitro cytotoxic effects in both cell cultures.  
Due to the influence of androgens in pain processes and the common opioid-
induced hypogonadism, in vivo studies were carried out to investigate their 
long-term administration in a pain model of persistent pain.  
Androgen therapy can also be required in neurodegenerative disorders, for 
instance in X-linked adrenoleukodystrophy, an inherited pathology. Lipid 
alterations are the major cause of the disorder and hypogonadism can be a 
secondary event. In this specific disorder and in chronic pathologies with 
unbalanced lipid and steroid hormone metabolism, the use of the described 
esters, which are more “physiological” than the ones currently available, 
should be carefully considered. 
 
